Nexstim Receives NBS 6 System Order from US Customer

Press release, Helsinki, 9 October 2025 at 2 PM (EEST)

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from an existing customer in the United States. The customer is an experienced user of the Nexstim therapy system that is acquiring their fourth system.

The NBS 6 is a new generation Nexstim system that makes the Company's clinically established, e-field navigated TMS (transcranial magnetic stimulation) technology more user-friendly than ever before. The NBS 6 system is currently FDA-cleared for the treatment of major depressive disorder (MDD) in the United States.

Mikko Karvinen, CEO of Nexstim, comments: "We are happy to have such committed customers, including this western US -based clinic that operates in multiple locations. Like all of our customer hospitals and clinics, this TMS therapy provider shares our mission of creating possibilities for better lives, and we are excited to follow their story."

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

[email protected]

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the NBS System 5 and NBS 6. The NBS System 5 is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. The NBS System 6 is CE-marked for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit https://www.nexstim.com